https://www.zacks.com/stock/news/2283577/bristol-myers-bmy-reports-positive-data-on-breyanzi-opdivo?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2283577
Jun 04, 2024 - Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
zc:3121287515294939092
0
https://www.zacks.com/stock/news/2281590/bristol-myers-bmy-gets-ec-nod-for-opdivo-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2281590
May 30, 2024 - Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
zc:-1255526950583232407
0
https://www.zacks.com/stock/news/2280718/prothena-prta-bristol-myers-tie-up-for-second-neuro-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2280718
May 29, 2024 - Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
zc:-1927422890470025962
0
https://www.zacks.com/stock/news/2277541/bristol-myers-bmy-updates-action-date-for-subcutaneous-opdivo?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2277541
May 22, 2024 - The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
zc:5391411465561947834
0
https://www.zacks.com/stock/news/2275062/biotech-stock-roundup-nvax-fulc-up-on-deals-with-sny-updates-from-mrna-bmy?cid=CS-ZC-FT-analyst_blog|stock_roundup-2275062
May 16, 2024 - Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
zc:-5144554873498763555
0
https://www.zacks.com/stock/news/2272954/bristol-myers-bmy-fails-to-meet-goal-in-opdivo-nsclc-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2272954
May 13, 2024 - Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
zc:5466218521901542429
0
https://www.fool.com/investing/2024/05/10/2-beaten-down-stocks-to-buy-and-hold-for-10-years/?source=iedfolrf0000001
May 10, 2024 - They offer plenty of upside and solid dividend growth.
0
fool:-4921813327635271063
0
https://www.zacks.com/stock/news/2269782/a-look-at-pharma-etfs-post-q1-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2269782
May 07, 2024 - Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
zc:5661493127721587987
0
https://www.zacks.com/stock/news/2262685/biotech-stock-roundup-biib-bmy-s-q1-earnings-incy-s-acquisition-updates-from-vrtx?cid=CS-ZC-FT-analyst_blog|earnings_article-2262685
Apr 25, 2024 - Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
zc:8506602132430980156
0
https://www.zacks.com/stock/news/2262549/bristol-myers-bmy-q1-earnings-taking-a-look-at-key-metrics-versus-estimates-revised?cid=CS-ZC-FT-fundamental_analysis|nfm-2262549
Apr 25, 2024 - While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zc:5383185858909909157
0